These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 26226846)

  • 21. The Prognostic and Predictive Role of Epidermal Growth Factor Receptor in Surgical Resected Pancreatic Cancer.
    Guo M; Luo G; Liu C; Cheng H; Lu Y; Jin K; Liu Z; Long J; Liu L; Xu J; Huang D; Ni Q; Yu X
    Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27399694
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.
    Sinicrope FA; Shi Q; Smyrk TC; Thibodeau SN; Dienstmann R; Guinney J; Bot BM; Tejpar S; Delorenzi M; Goldberg RM; Mahoney M; Sargent DJ; Alberts SR
    Gastroenterology; 2015 Jan; 148(1):88-99. PubMed ID: 25305506
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IL17RB expression might predict prognosis and benefit from gemcitabine in patients with resectable pancreatic cancer.
    Song Y; Ji B; Jiang CX; Chen ZM; Yao NH; Mukaida N; Huang H
    Pathol Res Pract; 2019 Dec; 215(12):152650. PubMed ID: 31585811
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does adjuvant therapy improve overall survival for stage IA/B pancreatic adenocarcinoma?
    Ostapoff KT; Gabriel E; Attwood K; Kuvshinoff BW; Nurkin SJ; Hochwald SN
    HPB (Oxford); 2017 Jul; 19(7):587-594. PubMed ID: 28433254
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma.
    Connor AA; Denroche RE; Jang GH; Timms L; Kalimuthu SN; Selander I; McPherson T; Wilson GW; Chan-Seng-Yue MA; Borozan I; Ferretti V; Grant RC; Lungu IM; Costello E; Greenhalf W; Palmer D; Ghaneh P; Neoptolemos JP; Buchler M; Petersen G; Thayer S; Hollingsworth MA; Sherker A; Durocher D; Dhani N; Hedley D; Serra S; Pollett A; Roehrl MHA; Bavi P; Bartlett JMS; Cleary S; Wilson JM; Alexandrov LB; Moore M; Wouters BG; McPherson JD; Notta F; Stein LD; Gallinger S
    JAMA Oncol; 2017 Jun; 3(6):774-783. PubMed ID: 27768182
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of Germline Variants in Human DNA Damage Repair Genes and Response to Adjuvant Chemotherapy in Resected Pancreatic Ductal Adenocarcinoma.
    Hu H; Zhu Y; Pu N; Burkhart RA; Burns W; Laheru D; Zheng L; He J; Goggins MG; Yu J
    J Am Coll Surg; 2020 Nov; 231(5):527-535.e14. PubMed ID: 32659497
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Response to Chemotherapy and Prognosis in Metastatic Colorectal Cancer With DNA Deficient Mismatch Repair.
    Alex AK; Siqueira S; Coudry R; Santos J; Alves M; Hoff PM; Riechelmann RP
    Clin Colorectal Cancer; 2017 Sep; 16(3):228-239. PubMed ID: 28063788
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DNA mismatch repair gene polymorphisms affect survival in pancreatic cancer.
    Dong X; Li Y; Hess KR; Abbruzzese JL; Li D
    Oncologist; 2011; 16(1):61-70. PubMed ID: 21212431
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survival Trends for Resectable Pancreatic Cancer Using a Multidisciplinary Conference: the Impact of Post-operative Chemotherapy.
    Syed AR; Carleton NM; Horne Z; Dhawan A; Bedi G; Kochhar G; Morrissey S; Williams H; Atkinson D; Schiffman S; Monga D; Lupetin A; Kirichenko A; Mitre M; Dhawan M; Kulkarni A; Thakkar S
    J Gastrointest Cancer; 2020 Sep; 51(3):836-843. PubMed ID: 31605289
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future.
    Christenson ES; Jaffee E; Azad NS
    Lancet Oncol; 2020 Mar; 21(3):e135-e145. PubMed ID: 32135117
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of microRNA-21 expression with its targets, PDCD4 and TIMP3, in pancreatic ductal adenocarcinoma.
    Nagao Y; Hisaoka M; Matsuyama A; Kanemitsu S; Hamada T; Fukuyama T; Nakano R; Uchiyama A; Kawamoto M; Yamaguchi K; Hashimoto H
    Mod Pathol; 2012 Jan; 25(1):112-21. PubMed ID: 21983937
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.
    Sinicrope FA; Foster NR; Thibodeau SN; Marsoni S; Monges G; Labianca R; Kim GP; Yothers G; Allegra C; Moore MJ; Gallinger S; Sargent DJ
    J Natl Cancer Inst; 2011 Jun; 103(11):863-75. PubMed ID: 21597022
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DNA mismatch repair abnormalities in acinar cell carcinoma of the pancreas: frequency and clinical significance.
    Liu W; Shia J; Gönen M; Lowery MA; O'Reilly EM; Klimstra DS
    Pancreas; 2014 Nov; 43(8):1264-70. PubMed ID: 25058881
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Breast cancer resistance protein expression is associated with early recurrence and decreased survival in resectable pancreatic cancer patients.
    Lee SH; Kim H; Hwang JH; Lee HS; Cho JY; Yoon YS; Han HS
    Pathol Int; 2012 Mar; 62(3):167-75. PubMed ID: 22360504
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
    Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
    World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A correlation study of mismatch repair immunohistochemical protein expression of pancreatic solid tumors in cytology cell blocks and matching surgical specimens.
    Teodosescu A; Chan I; Elder J; Wu M
    Diagn Cytopathol; 2021 Jun; 49(6):700-705. PubMed ID: 33615705
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DNA mismatch repair deficiency in breast carcinoma: a pilot study of triple-negative and non-triple-negative tumors.
    Wen YH; Brogi E; Zeng Z; Akram M; Catalano J; Paty PB; Norton L; Shia J
    Am J Surg Pathol; 2012 Nov; 36(11):1700-8. PubMed ID: 22992699
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Strong prognostic value of nodal and bone marrow micro-involvement in patients with pancreatic ductal carcinoma receiving no adjuvant chemotherapy.
    Yekebas EF; Bogoevski D; Bubenheim M; Link BC; Kaifi JT; Wachowiak R; Mann O; Kutup A; Cataldegirmen G; Wolfram L; Erbersdobler A; Klein C; Pantel K; Izbicki JR
    World J Gastroenterol; 2006 Oct; 12(40):6515-21. PubMed ID: 17072983
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DLL4 expression is a prognostic marker and may predict gemcitabine benefit in resected pancreatic cancer.
    Drouillard A; Puleo F; Bachet JB; Ouazzani S; Calomme A; Demetter P; Verset G; Van Laethem JL; Maréchal R
    Br J Cancer; 2016 Nov; 115(10):1245-1252. PubMed ID: 27755532
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical application of the biomarkers for the selection of adjuvant chemotherapy in pancreatic ductal adenocarcinoma.
    Oba A; Ban D; Kirimura S; Akahoshi K; Mitsunori Y; Matsumura S; Ochiai T; Kudo A; Tanaka S; Minoru T
    J Hepatobiliary Pancreat Sci; 2016 Aug; 23(8):480-8. PubMed ID: 27247050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.